Highlights Artelo Biosciences, Inc.

Equities

ARTL

US04301G5080

Delayed Nasdaq Other stock markets 21:30:00 16/05/2024 BST			5-day change	1st Jan Change
1.36 ^USD	+3.02%		-2.16%	-2.86%

04-23	Transcript : Artelo Biosciences, Inc. - Special Call
04-23	Artelo Biosciences, Inc. Announces Publication of Peer-Reviewed Article Highlighting FABP7 as a Promising Novel Target in Cancer Therapy	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Artelo Biosciences, Inc. Announces Publication of Peer-Reviewed Article Highlighting FABP7 as a Promising Novel Target in Cancer Therapy	04-23	CI
Artelo Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-25	CI
Artelo Biosciences, Inc. Announces Publication of New Peer-Reviewed Pre-Clinical Research Demonstrating ART26.12's Effectiveness in Treating and Preventing Oxaliplatin-Induced Peripheral Neuropathy	01-23	CI
Artelo Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13	CI
Artelo Biosciences to Present Preclinical Data Showcasing Research on ART26.12 and ART12.11 in Anxiety and Depression at Neuroscience 2023	11-02	CI
Artelo Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	10/08/23	CI
Artelo Biosciences Selects for Oral Presentation to Report Positive Research Findings on Art12.11	07/06/23	CI
Artelo Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	11/05/23	CI
Artelo Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	31/03/23	CI
Artelo Biosciences Completes Enrollment of the Phase 1b Stage of its CAReS Clinical Trial Evaluating ART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss	02/02/23	CI
Artelo Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	08/11/22	CI
Artelo Biosciences, Inc. Reports Positive Pre-Clinical Results with its Novel Inhibitor to Fatty Acid Binding Protein 5	16/08/22	CI
Artelo Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	09/08/22	CI
Artelo Biosciences, Inc. Completes Enrollment of the First Three Cohorts in its CAReS Study Evaluating ART27.13	19/07/22	CI
Artelo Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	12/05/22	CI
Artelo Biosciences, Inc. Reports Positive Pre-Clinical Results for Lead Program in Cancer-Related Cachexia	13/04/22	CI
Artelo Biosciences, Trinity College Dublin Agree to Expand Partnership	28/03/22	MT
Artelo Biosciences Receives Patent Covering Means for Treating Medical Conditions Using Cannabidiol Cocrystal Composition	02/03/22	MT
Artelo Biosciences, Inc. Reports Earnings Results for the First Quarter Ended November 30, 2021	12/01/22	CI
Artelo Biosciences' Lead Cannabinoid No Longer Schedule 1 Controlled Substance in UK; Shares Rise Pre-Bell	11/01/22	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Artelo Biosciences, Inc.

Equities

ARTL

US04301G5080

Highlights

Filters